-
Designing Clinical Trials for the Patient
Challenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
-
Treating Smoldering Multiple Myeloma
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
-
Immunotherapy Improves Survival in Bladder Cancer
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
-
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer
Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
-
Delaying Treatment Resistance
Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
2024: The Year in Cancer News
The Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff
-
Cancer Today Editors’ Picks: 2024
Our favorite Cancer Today stories from 2024, as picked by the editors.
-
Rethinking the Role of Radiation
Chest radiation may not be necessary for people with intermediate-risk breast cancer.
by Thomas Celona
-
De-escalating Treatment for DCIS
Research finds certain people with low-risk DCIS may be able to forgo surgery or radiation.
by Thomas Celona
-
Study Highlights Challenges in Pancreatic Cancer Staging
Most pancreatic ductal adenocarcinoma cases initially considered to be stage I are changed to a higher stage after surgery.
by Taneia Surles
Cancer Talk
Family of Henrietta Lacks Works for ‘Health Intelligence’
Alfred Lacks Carter Jr. and other family members honor the legacy of Henrietta Lacks by helping others better understand their health care.
by Kevin McLaughlin
Researchers Tackle Immune-related Adverse EffectsScientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona